TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12942871
Drug: Fermented soy
Normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented soy milk (200 ml daily)
Study: 12942871
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 ml chemically fermented)
Study: 1354086
Drug: Epanolol, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epanolol, 200 mg o.d.
Study: 1354086
Drug: Atenolol, 100
Normalized name: Atenolol, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 100 mg o.d.
Study: 30616140
Drug: Low-charge electrotherapy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-charge electrotherapy (LCE), administered three times a week, approximately 2.8 Joules
Study: 27412415
Drug: BCG revaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG revaccination after isoniazid preventive therapy (IPT)
Study: 6147551
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate 600 mg a day for 7 days
Study: 24672331
Drug: Intensive atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive atorvastatin group (I‐A group)
Study: 23290037
Drug: Roxithromycin disperse
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin disperse tablet 0.15 g every day and ambroxol hydrochloride tablet 90 mg 3 times a day
Study: 23290037
Drug: Ambroxol hydrochloride
Normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol hydrochloride tablet 90 mg 3 times a day
Study: 15692221
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg b.i.d. for 4 days
Study: 15692221
Drug: Ibuprofen 80
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 80 mg b.i.d. for 4 days
Study: 10423311
Drug: Aerosolized ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aerosolized ribavirin high dose (6 g/100 mL over 2 hr, three times a day)
Study: 10423311
Drug: Aerosolized ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aerosolized ribavirin regular dose (6 g/300 mL over 18 hr/day)
Study: 7557855
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa 3 mIU three times weekly for 6 months
Study: 2164528
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (E) 10 mg orally
Study: 30738995
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol consumption (<10 g/day)
Study: 28088839
Drug: TAK-648 (PDE4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-648 (PDE4 inhibitor) at doses of 0.05-0.85 mg in healthy volunteers
Study: 28088839
Drug: TAK-648 (PDE4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-648 (PDE4 inhibitor) at a daily dose of 0.1 mg
Study: 25636072
Drug: Ivabradine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (10 mg twice a day for 6 weeks)
Study: 25636072
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg twice a day for 6 weeks)
Study: 18469148
Drug: Nitro-l-arginine (NLA)
Normalized name: Ngamma-Nitro-L-arginine
DrugBank: Nitroarginine (DB04223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitro-l-arginine (NLA)
Study: 16950434
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (SEPS combined with superficial vein ligation)
Study: 16950434
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (ambulatory compression therapy)
Study: 2498620
Drug: Kliogest (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kliogest (continuous treatment)
Study: 2498620
Drug: Trisequens (sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trisequens (sequential treatment)
Study: 1091856
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous injection of heparin
Study: 1091856
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of heparin
Study: 1091856
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with laboratory control (partial thromboplastin time)
Study: 1091856
Drug: Heparin without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin without laboratory control
Study: 30889093
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of isoflavones (10mg, n = 35)
Study: 30889093
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of isoflavones (35mg, n = 37)
Study: 30889093
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of isoflavones (60mg, n = 29)
Study: 30889093
Drug: Overall sample
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall sample (all doses)
Study: 25953600
Drug: Novel low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel low energy-dense semi-solid food (0.72kcal/g)
Study: 25953600
Drug: Higher energy-dense
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher energy-dense semi-solid food (1.57kcal/g)
Study: 1362320
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine alone (group I)
Study: 1362320
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine in combination with HBIG (group II)
Study: 3932033
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of prednisone, azathioprine, cyclophosphamide, Heparoid Spofa forte ling., Heparin retard Spofa and dipyridamole
Study: 29654643
Drug: Sitagliptin 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 0 mg (placebo)
Study: 27068582
Drug: Postoperative patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative patient-controlled intravenous analgesia
Study: 24304349
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of daily supervised consumption of OMT
Study: 24304349
Drug: 1 month
Normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 month or less of daily supervised OMT, then daily unsupervised consumption
Study: 24304349
Drug: 1 month
Normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 month or less of daily unsupervised consumption
Study: 15253170
Drug: Transdermal therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapeutic system fentanyl (TTS-F)
Study: 12435175
Drug: Capecitabine and
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine and docetaxel combination treatment
Study: 12435175
Drug: Poststudy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poststudy treatment with capecitabine
Study: 12435175
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (capecitabine/docetaxel)
Study: 8110697
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release acetazolamide (500 mg twice a day)
Study: 113143
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg orally followed by TRH intravenously
Study: 113143
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg orally followed by placebo injection
Study: 113143
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet followed by TRH intravenously
Study: 113143
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet followed by placebo injection
Study: 27834619
Drug: Low-dose plyometric
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose plyometric training (PT), 60 foot contacts, twice-weekly for 6 weeks
Study: 27834619
Drug: Low-dose plyometric
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose plyometric training (PT) in Mid-PHV group
Study: 27834619
Drug: Low-dose plyometric
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose plyometric training (PT) in Pre-PHV group
Study: 11722314
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT), 10 sessions including cognitive methods, behavioural methods, problem-solving skills training, and behavioural counselling to significant others.
Study: 11722314
Drug: Routine medical
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medical treatment (Control group)
Study: 9393272
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment or information provided to the control group
Study: 3259337
Drug: Thiopental (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (4.0 mg/kg)
Study: 26183034
Drug: Goal-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed fluid therapy (GDFT) with the LiDCOrapid system
Study: 26183034
Drug: Routine fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine fluid therapy (Control)
Study: 20006169
Drug: Thermosetting gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermosetting gel containing 2.5% prilocaine and 2.5% lidocaine
Study: 20006169
Drug: Thermosetting gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermosetting gel
Study: 9874712
Drug: Low-dose thalidomide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose thalidomide (200 mg, escalated to 1200 mg)
Study: 9874712
Drug: High-dose thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose thalidomide (200 mg, escalated to 1200 mg)
Study: 8911877
Drug: Flosequinan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan (100 mg daily)
Study: 1806811
Drug: Oral DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral DDAVP (150 to 600 micrograms/day)
Study: 1806811
Drug: Intranasal DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal DDAVP
Study: 6441815
Drug: Prostaglandin synthetase
Normalized name: nitric oxide synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin synthetase promoter (263E) 500 mg three times daily
Study: 31577678
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics for 24 hours
Study: 31577678
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics for 72 hours
Study: 27354766
Drug: Nebulized magnesium
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized magnesium sulfate (MgSO4) and salbutamol combination
Study: 24381294
Drug: fMRI decoding
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fMRI decoding of spoken words in one language (e.g., 'horse' in English)
Study: 21706151
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) add-on to riluzole, initial dose of 2 IU s.c. every other day, progressively increased to a maximum of 8 IU.
Study: 21706151
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) add-on to riluzole
Study: 21203523
Drug: Alum-adjuvanted H5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adjuvanted H5 VLP vaccine (5, 10, or 20 µg)
Study: 21203523
Drug: Alum-adjuvanted H5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adjuvanted H5 VLP vaccine (10 or 20 µg)
Study: 21203523
Drug: Alum-adjuvanted H5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adjuvanted H5 VLP vaccine (all doses)
Study: 17882705
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone eyedrops
Study: 12020141
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention program (11-week duration) including education, environmental modifications, exercise programs, drug regimen reviews, provision of hip protectors, and post-fall conferences.
Study: 8570882
Drug: Low-dose ofloxacin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ofloxacin (OFLX) and erythromycin (EM) therapy daily for 6 months
Study: 8570882
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment of OFLX and EM therapy for 6 months
Study: 8570882
Drug: Erythromycin (EM)
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin (EM) therapy for 6 months
Study: 8570882
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (neither OFLX nor EM therapy)
Study: 30173058
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) or Acceptance and Commitment Therapy (ACT)
Study: 21434340
Drug: Chaipo Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaipo Granule (CPG) 3 pouches twice a day for 24 weeks
Study: 21434340
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (salmeterol and fluticasone propionate, salbutamol + ipratropium bromide)
Study: 19842560
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (2‐4 U/h)
Study: 19842560
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy (no insulin administration)
Study: 14593127
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (including percutaneous transluminal angioplasty, balloon-expandable stent, self-expandable stent)
Study: 10924782
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A/B vaccine (Twinrix Adult)
Study: 10924782
Drug: Monovalent vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent vaccines (Havrix 1440+Engerix‐B or Vaqta+Gen H‐B‐Vax)
Study: 1583173
Drug: Calcipotriol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol (50 micrograms/gm) ointment
Study: 1583173
Drug: Betamethasone 17-valerate
Normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 17-valerate (1 mg/gm) ointment
Study: 25475247
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine rehabilitation (IMR) group receiving acupuncture and Chinese herbs in addition to basic Western medicine and rehabilitation treatment.
Study: 25475247
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation (CR) group not receiving acupuncture and Chinese herbal medicine.
Study: 25475247
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine rehabilitation (IMR) group
Study: 20823897
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (5‐formyltetrahydrofolate) at a dosage of 70 μg/kg/day for 2 weeks
Study: 20823897
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no folinic acid treatment)
Study: 18257178
Drug: Cisapride, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 10 mg orally, three times a day.
Study: 15694243
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug exposure)
Study: 9223023
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg, qid) in REFLUX-group (N = 43)
Study: 9223023
Drug: Domperidone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (20 mg, tid) in REFLUX-group (N = 43)
Study: 9223023
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg, qid) in DYSPEPSIA-group (N = 84)
Study: 9223023
Drug: Domperidone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (20 mg, tid) in DYSPEPSIA-group (N = 84)
Study: 9223023
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (Cisapride and Domperidone)
Study: 8354325
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 5 mg, inhaled four times a day for 3 weeks
Study: 8354325
Drug: Placebo, inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, inhaled four times a day for 3 weeks
Study: 31495952
Drug: 0.025 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg/kg teduglutide
Study: 31495952
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg teduglutide
Study: 27852236
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) 200 mg
Study: 11177199
Drug: HIFAT (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFAT (1.2 g saturated fat/kg BM with 3500 U heparin intravenously)
Study: 11177199
Drug: CHO (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (2.5 g carbohydrate/kg BM)
Study: 11177199
Drug: NA (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA (2.5 g carbohydrate + 20 mg nicotinic acid/kg BM)
Study: 1482131
Drug: Antibiotic combination
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic combination therapy (beta-lactam plus aminoglycoside)
Study: 1482131
Drug: Monotherapy (beta-lactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (beta-lactam or aminoglycoside)
Study: 4018499
Drug: Cimetidine bolus
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine bolus administration (up to 300 mg every 6 h, 1200 mg/day)
Study: 4018499
Drug: Cimetidine primed
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine primed infusion (up to 50 mg/h, 1200 mg/day)
Study: 4018499
Drug: Cimetidine infusion
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine infusion
Study: 29036480
Drug: Mandible advanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandible advanced device (MAD) therapy
Study: 29036480
Drug: Group OSAHS
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group OSAHS (induced OSAHS without treatment)
Study: 27343983
Drug: Cell culture-derived
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell culture-derived trivalent influenza vaccine (TIVc)
Study: 27343983
Drug: Egg-derived trivalent
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg-derived trivalent influenza vaccine (TIV)
Study: 25045360
Drug: Patient-based combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-based combined symptom medication score
Study: 18826358
Drug: Cyclosporine (1.25-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (1.25-5 mg/kg/day) administered intravenously, initiated within 8 hours of injury, in 2 divided doses or continuous infusion over 72 hours.
Study: 18826358
Drug: Placebo treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, initiated within 8 hours of injury.
Study: 16193496
Drug: Levalbuterol (LEV)
DrugBank: Levosalbutamol (DB13139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levalbuterol (LEV) 0.31 mg
Study: 16193496
Drug: Levalbuterol (LEV)
DrugBank: Levosalbutamol (DB13139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levalbuterol (LEV) 0.63 mg
Study: 16193496
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol (RAC) 1.25 mg (for children <33 lb)
Study: 16193496
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol (RAC) 2.5 mg (for children >/=33 lb)
Study: 10359887
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate powder, 500 microgram, twice daily
Study: 7677297
Drug: Resistance to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance to thyroid hormone
Study: 2371802
Drug: Propofol in
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol in emulsion (Diprivan) - bolus of 2 mg/kg followed by infusion of 6 mg/kg/h for one hour.
Study: 2371802
Drug: Intralipid 10%
Normalized name: Intralipid 10% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 10% - bolus of 0.2 mg/kg followed by infusion of 0.6 ml/kg/h for one hour.